New hope for sarcopenic obesity: expanded access program opens
NCT ID NCT06784297
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program offers expanded access to IMM01-STEM, an experimental treatment for sarcopenic obesity—a condition combining muscle loss and obesity. It is for patients who cannot join ongoing clinical trials due to location, eligibility, or other reasons. Participants receive weekly injections for four weeks. The goal is to provide potential benefit while more data is collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IMM01-STEM (a stem cell-derived protein injection)
- What this could lead to
- If successful, this could provide a treatment option for people with sarcopenic obesity who cannot join standard clinical trials.
- What could go wrong
- This is an expanded access program, not a full clinical trial, so data on effectiveness and safety is limited. The treatment is still experimental.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY AND OBESITY-RELATED MEDICAL CONDITIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can nerve changes explain Age-Related muscle loss?
- Muscle loss in aging: can diet and exercise turn back the clock?
- Could a simple CT scan reveal which ICU cancer patients are at highest risk?
- Muscle-Saving supplement may shield seniors from Weight-Loss drug side effect
- Can surgery for stomach or esophageal cancer cloud the mind?